[The serum concentration of interleukin-2 in a hemodialysis patient--report from interleukin adjuvant therapy for local recurrent renal cancer].

Abstract

We started interleukin-2 (IL-2) adjuvant therapy after resection of a repeated local recurrence of renal cell carcinoma in a hemodialysis patient. It is reported that IL-2 is mainly metabolized in proximal tubules of the kidney. To determine the IL-2 concentration, we employed the ELISA method using anti-human IL-2 antibodies. At the concentration of 350,000 Japan reference unit (JRU) in a hemodialysis patient, the change in serum IL-2 was almost the same speed compared to 700,000 JRU in normal renal function patients, which was reported previously. This report may also be a good tool to define the ideal dose of IL-2 in hemodialysis patients.

• Authors: Osamu Ishizuka, Tomoaki Tanabe, Tsuyoshi Nakayama, Yoshiaki Kinebuchi, Teruyuki Ogawa, Osamu Nishizawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 33 Issue 3 Pg. 389-90 (Mar 2006) ISSN: 0385-0684 [Print] Japan
• PMID: 16531726 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Adjuvants, Pharmaceutic
• Antineoplastic Agents
• Interleukin-2

Topics

• Adjuvants, Pharmaceutic (administration & dosage)
• Adult
• Antineoplastic Agents (administration & dosage)
• Carcinoma, Renal Cell (blood, drug therapy)
• Humans
• Interleukin-2 (administration & dosage, blood)
• Kidney Failure, Chronic (therapy)
• Kidney Neoplasms (blood, drug therapy)
• Male
• Neoplasm Recurrence, Local (blood, drug therapy)
• Renal Dialysis